Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Journal of the American Academy of Dermatology Feb 11, 2018
Guttman-Yassky E, et al. - In patients with moderate-to-severe atopic dermatitis (AD), the efficacy and safety of baricitinib were evaluated in a randomized trial. The inflammation and pruritus in patients with moderate-to-severe AD was reduced by use of baricitinib along with topical corticosteroids (TCS).
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
